Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis

Drug Safety

Volumn 32, Issue 3, 2009, Pages 219-228

  Loke, Yoon Kong ^a   Jeevanantham, Vinodh ^b   Singh, Sonal ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DATA ANALYSIS; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; STROKE; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE;

EID: 63849083483     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932030-00004     Document Type: Article

References (31)

1. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
2. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344-52
3. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344 (5): 333-40
4. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15 (6): 1006-13
5. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42 (11): 2309-18
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (1996): 1535-41
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 (24): 2077-82
8. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356 (18): 1809-22
9. Lyles KW, Colón-Emeric CS, Magaziner JS, et al., for the HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809
10. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18 (1): 25-34
11. American Dental Association. Report of the Council of Scientific Affairs: expert panel recommendations. Dental management of patients on oral bisphosphonate therapy, June 2006 [online]. Available from URL: http://www.ada.org/prof/resources/topics/osteonecrosis.asp [Accessed 2008 Jan 27]
12. US Food and Drug Administration. Early communication of an ongoing safety review [online]. Available from URL: http://www.fda.gov/cder/drug/early-comm/ bisphosphonates. htm [Accessed 2008 Jan 27]
13. US Food and Drug Administration. What is a serious adverse event? [online]. Available from URL: http://www.fda.gov/medwatch/report/DESK/advevnt. htm [Accessed 2008 Feb 22]
14. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.0. The Cochrane Collaboration, 2008 [online]. Available from URL: http://www.cochrane-handbook.org [Accessed 2009 Feb 5]
15. Deeks JJ, Higgins JP, Altman DG. Identifying and measuring heterogeneity. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.0. The Cochrane Collaboration, 2008 [online]. Available from URL: http://www.cochranehandbook.org [Accessed 2009 Feb 5]
16. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007; 356 (18): 1895-6
17. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med 2007; 357: 712-3
18. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402
19. Novartis PharmaceuticalsUKLtd. Zometa: last updated Jul 4, 2008 [online]. Available fromURL: http://emc.medicines. org.uk/emc/assets/c/html/displaydoc. asp?documentid= 14062. [Accessed 2008 Sep 23]
20. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336: 813-6
21. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168: 826-31
22. Merck. Statement by Merck & Co., Inc., regarding the fracture intervention trial (FIT) with FOSAMAX® (alendronate sodium) and incidence of atrial fibrillation [online]. Available from URL: http://www.merck.com/ newsroom/press-releases/product/2007-0502.html [Accessed 2008 Jan 27]
23. Cummings SR, Mesenbrink P, Eriksen EF, et al. Risk factors for serious adverse events of atrial fibrillation in the Horizon-PFT trial of zoledronic acid [abstract no. 1056]. Presented at 29th AnnualMeeting of the American Society for Bone andMineral Research; 2007 Sep 16-19; Honolulu
24. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10
25. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates.Curr Osteoporos Rep 2003; 1 (2): 45-52
26. Kadar E, Rush JE, Wetmore L, et al. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy. J Am Anim Hosp Assoc 2004; 40 (1): 75-81
27. Elisaf M, Kalaitzidis R, Siamopoulos KC. Multiple electrolyte abnormalities after pamidronate administration. Nephron 1998; 79 (3): 337-9
28. Schussheim DH, Jacobs TP, Silverberg SJ. Hypocalcemia associated with alendronate [letter]. Ann Intern Med 1999; 130: 329
29. Ruigómez A, Johansson S, Wallander MA, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55 (4): 358-63
30. US Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates [online]. Available from URL: http://www.fda.gov/Cder/Drug/ early-comm/bisphosphonates-update-200811.htm [Accessed 2009 Feb 5]
31. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. Epub 2009 Jan 6